SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 197.99 |
| Enterprise Value ($M) | 70.61 |
| Book Value ($M) | 115.63 |
| Book Value / Share | 10.57 |
| Price / Book | 1.71 |
| NCAV ($M) | 110.07 |
| NCAV / Share | 10.06 |
| Price / NCAV | 1.80 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.01 |
| Return on Assets (ROA) | -1.80 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.54 |
| Current Ratio | 3.54 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 156.77 |
| Assets | 162.33 |
| Liabilities | 46.70 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Vivo Opportunity Fund Holdings, L.P. | 5.50 | ||
| 13G | Venrock Healthcare Capital Partners III, L.P. | 9.99 | ||
| 13G | TCG Crossover GP II, LLC | 9.20 | ||
| 13D/A | Ra Capital Management, L.p. | 9.99 | 55.43 | |
| 13G/A | Biotechnology Value Fund L P | 9.99 | -92.42 | |
| 13G | Canaan XII L.P. | 9.99 | ||
| 13G | BCLS Fund III Investments, LP | 9.99 | ||
| 13G/A | Point72 Asset Management, L.P. | 1.40 | -67.68 | |
| 13G/A | Nantahala Capital Management, LLC | 1.70 | -64.58 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 16,652 | 72,416 | 22.99 | |
| 14,716 | 67,932 | 21.66 | |
| 9,498 | 29,480 | 32.22 | |
| 17,787 | 67,821 | 26.23 | |
| 11,642 | 46,966 | 24.79 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CASI – CASI Pharmaceuticals, Inc. | CDIO – Cardio Diagnostics Holdings, Inc. |
| CDMO – Avid Bioservices, Inc. | CDXC – ChromaDex Corporation |
| CELU – Celularity Inc. |
Financial data and stock pages provided by
Fintel.io